Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Go back to Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 219.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $219.07 | 52 Week High | $333.65 | |||
| Open | $219.07 | 52 Week Low | $223.02 | |||
| Day High | $219.07 | P/E | 28.05 | |||
| Day Low | $219.07 | EPS | $7.81 | |||
| Volume | 380 | |||||
